Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moluodan is a traditional Chinese patent medicine formulated as a concentrated herbal pill. It is primarily used for the treatment of chronic atrophic gastritis (CAG) and related digestive disorders such as gastralgia, flatulence, anorexia, eructation (belching), and pyrosis (heartburn)[1][3][5]. Clinical studies have shown that Moluodan can improve pathological examination outcomes, gastroscopy findings, and clinical symptoms in patients with CAG. It has also demonstrated efficacy in reversing gastric precancerous lesions—especially dysplasia—and may slow disease progression[1][2]. Mechanistic studies suggest that its therapeutic effects are mediated through modulation of key signaling pathways involved in inflammation and cell proliferation. Specifically, it acts on the tumor necrosis factor (TNF)/PI3K/AKT signaling pathway[3], inhibits the Wnt/β-catenin pathway[8], and downregulates expression of epidermal growth factor (EGF) and c-Myc to repair gastric mucosa and delay progression to precancerous lesions or gastric cancer[8]. The formula contains multiple active compounds derived from traditional Chinese medicinal herbs such as Anemone altaica Fisch., but its precise composition may vary by manufacturer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moluodan.